<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335085</url>
  </required_header>
  <id_info>
    <org_study_id>KU 2479/3-1</org_study_id>
    <nct_id>NCT03335085</nct_id>
  </id_info>
  <brief_title>Oxytocin Administration and Emotion Recognition Abilities in Adults Reporting Adverse Childhood Experiences</brief_title>
  <official_title>Long-term Consequences of Childhood Adversity: Exploring Stress Responsive Molecular Pathways and Psychobiological Intervention Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether intranasal administration of a single dose of oxytocin improves
      the ability to recognize emotional states. In a cross-over design, half of the participants
      first received oxytocin, the other half first received placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adverse childhood experience such as neglect or abuse can lead to long-term deficits in
      emotion processing abilities, and these effects might be mediated via alterations in oxytocin
      production or sensitivity. The goal of this study was to test whether emotion recognition
      abilities and empathy might be improved by intranasal oxytocin administration in adults with
      a history of childhood maltreatment.

      In a double-blind, placebo-controlled experiment with a crossover design, we assessed the
      performance of 40 healthy participants with a history of childhood adversity on the Reading
      the Mind in the Eyes Test (RMET) and an emotion recognition task under 24 IU oxytocin vs.
      placebo and compared them to a control group of 40 matched individuals without traumatic
      childhood experiences.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2011</start_date>
  <completion_date type="Actual">November 5, 2013</completion_date>
  <primary_completion_date type="Actual">March 23, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reading the Mind in the Eyes Test</measure>
    <time_frame>45 minutes post-dose</time_frame>
    <description>Requires participants to infer complex mental states fromthe eye region</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gradual Emotion Recognition Test</measure>
    <time_frame>50 minutes post-dose</time_frame>
    <description>Requires participants to swiftly and accurately detect basic emotions form naturalistic, animated stimuli.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All ingredients except for oxytocin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ presence of moderate to severe experiences of childhood adversity (early adversity group)

        Exclusion Criteria:

          -  Acute psychiatric disorders and personality disorders or psychiatric disorders within
             the last 12 months

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Prof. Robert Kumsta</investigator_full_name>
    <investigator_title>Professor of Genetic Psychology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

